Andrew J Leidner1, Neil Murthy2, Harrell W Chesson3, Matthew Biggerstaff4, Charles Stoecker5, Aaron M Harris3, Anna Acosta4, Kathleen Dooling4, Carolyn B Bridges6. 1. Berry Technology Solutions, USA. Electronic address: aleidner@cdc.gov. 2. National Center for Immunization and Respiratory Diseases, CDC, USA; Epidemic Intelligence Service, CDC, USA. 3. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA. 4. National Center for Immunization and Respiratory Diseases, CDC, USA. 5. School of Public Health and Tropical Medicine, Tulane University, USA. 6. Berry Technology Solutions, USA.
Abstract
BACKGROUND: Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule. METHODS: We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios. RESULTS: The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations. CONCLUSIONS: The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations. Published by Elsevier Ltd.
BACKGROUND: Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule. METHODS: We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios. RESULTS: The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations. CONCLUSIONS: The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations. Published by Elsevier Ltd.
Authors: Bruce Y Lee; Kristina M Bacon; Julie M Donohue; Ann E Wiringa; Rachel R Bailey; Richard K Zimmerman Journal: Vaccine Date: 2011-01-06 Impact factor: 3.641
Authors: Nazila M Dabestani; Andrew J Leidner; Eric E Seiber; Hyoshin Kim; Samuel B Graitcer; Ivo M Foppa; Carolyn B Bridges Journal: Prev Med Date: 2019-05-29 Impact factor: 4.018
Authors: Giovanna Elisa Calabro'; Elettra Carini; Alessia Tognetto; Irene Giacchetta; Ester Bonanno; Marco Mariani; Walter Ricciardi; Chiara de Waure Journal: Front Public Health Date: 2022-03-09
Authors: Andrew J Leidner; Helen Fisun; Sean Trimble; Paul Lucas; Cameron Noblit; John M Stevenson Journal: Vaccine Date: 2020-02-25 Impact factor: 3.641